U.S. markets closed
  • S&P 500

    3,768.25
    -27.29 (-0.72%)
     
  • Dow 30

    30,814.26
    -177.24 (-0.57%)
     
  • Nasdaq

    12,998.50
    -114.10 (-0.87%)
     
  • Russell 2000

    2,123.20
    -32.15 (-1.49%)
     
  • Crude Oil

    52.11
    -0.25 (-0.48%)
     
  • Gold

    1,836.20
    +6.30 (+0.34%)
     
  • Silver

    24.97
    +0.10 (+0.42%)
     
  • EUR/USD

    1.2074
    -0.0010 (-0.08%)
     
  • 10-Yr Bond

    1.0970
    -0.0320 (-2.83%)
     
  • GBP/USD

    1.3575
    -0.0009 (-0.07%)
     
  • USD/JPY

    103.7090
    -0.0910 (-0.09%)
     
  • BTC-USD

    35,676.43
    -382.46 (-1.06%)
     
  • CMC Crypto 200

    694.30
    -40.85 (-5.56%)
     
  • FTSE 100

    6,720.65
    -15.06 (-0.22%)
     
  • Nikkei 225

    28,242.21
    -276.97 (-0.97%)
     

A Preview Of Core Laboratories's Earnings

Benzinga Insights
·2 min read

On Wednesday, October 21, Core Laboratories (NYSE: CLB) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.

What Are Earnings, Net Income, And Earnings Per Share (EPS)?

Earnings and EPS are useful metrics of profitability. Total earnings also known as net income is equal to total revenue minus total expenses. Dividing net income by the total number of shares outstanding yields EPS.

Earnings And Revenue

Wall Street analysts see Core Laboratories reporting earnings of $0.16 per share on revenue of $114.04 million. In the same quarter last year, Core Laboratories reported EPS of $0.5 on revenue of $173.20 million.

Why Analyst Estimates And Earnings Surprises Are Important

Analysts who cover this company will publish forward-looking estimates of its revenue and EPS each quarter. Averaging together every EPS and revenue prediction that each analyst makes about a given company yields the "consensus estimates." If the company posts earnings or revenue above or below the consensus estimate, the stock may move by a considerable margin.

View more earnings on CLB

If the company were to match the consensus estimate when it reports Wednesday, earnings would be down 68.0%. Revenue would be down 34.16% on a year-over-year basis. Core Laboratories's reported EPS has stacked up against analyst estimates in the past like this:

Quarter

Q2 2020

Q1 2020

Q4 2020

Q3 2019

EPS Estimate

0.10

0.35

0.37

0.49

EPS Actual

0.14

0.31

0.38

0.50

Revenue Estimate

115.35 M

153.86 M

156.04 M

171.79 M

Revenue Actual

115.74 M

152.40 M

156.78 M

173.20 M

Stock Performance

Shares of Core Laboratories were trading at $14.84 as of October 19. Over the last 52-week period, shares are down 65.48%. Given that these returns are generally negative, long-term shareholders are probably down going into this earnings release.

Do not be surprised to see the stock move on comments made during its conference call. Core Laboratories is scheduled to hold the call at 08:30:00 ET and can be accessed here: https://www.webcaster4.com/Webcast/Page/1000/37733

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.